pdf   xlsx method abbreviations

endometrial cancer, lenvatinib in association , meta-analysis of study results

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths (OS) 0.65 [0.55, 0.77]< 10%1 study (1/-)100.0 %NAnot evaluable crucial-
PFS (extension) 0.56 [0.48, 0.66]< 10%1 study (1/-)100.0 %NAnot evaluable important-
progression or deaths (PFS) 0.56 [0.47, 0.66]< 10%1 study (1/-)100.0 %NAnot evaluable important-
objective responses (ORR) 2.97 [2.12, 4.18]> 10%1 study (1/-)100.0 %NAnot evaluable non important-

safety endpoints 00

AE (any grade) 2.10 [0.19, 23.24]< 10%1 study (1/-)27.4 %NAnot evaluable non important-
AE (grade 3-5) 3.26 [2.19, 4.85]< 10%1 study (1/-)0.0 %NAnot evaluable non important-
AE leading to treatment discontinuation (any grade) 7.41 [4.88, 11.26]< 10%1 study (1/-)0.0 %NAnot evaluable non important-
SAE (any grade) 2.94 [2.20, 3.94]< 10%1 study (1/-)0.0 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons